
HER2 low-expression breast cancer included in Korean guidelines for 1st time
For the first time, HER2 low-expression breast cancer has been specified in national treatment guidelines, strengthening the recommendation for Enhertu (trastuzumab deruxtecan, T-DXd). This is expected to further expand the scope of HER2-targeted therapy …